Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q99424
UPID:
ACOX2_HUMAN
Alternative names:
3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA 24-hydroxylase; 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA oxidase; Trihydroxycoprostanoyl-CoA oxidase
Alternative UPACC:
Q99424; A6NF16; B2R8U5
Background:
Peroxisomal acyl-coenzyme A oxidase 2, also known as 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA 24-hydroxylase, plays a crucial role in bile acid synthesis. It specifically oxidizes the CoA esters of bile acid intermediates, showcasing versatility by targeting both short and long chain 2-methyl branched fatty acids. This enzyme's activity is pivotal in maintaining the balance of bile acid composition, essential for lipid digestion and nutrient absorption.
Therapeutic significance:
The enzyme's dysfunction is linked to Congenital bile acid synthesis defect 6, a disorder marked by liver fibrosis, cognitive impairment, and vitamin D deficiency, among other symptoms. Understanding the role of Peroxisomal acyl-coenzyme A oxidase 2 could open doors to potential therapeutic strategies, offering hope for targeted treatments that could correct the underlying biochemical pathways and alleviate the disease's manifestations.